Evidence map›Paper›PMID 42202046›Full record

ArticleScience translational medicine2026

Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.

Adam S Sperling, Benjamin A Derman, Sarah Nikiforow, Alejandro Alonso, Shuntaro Ikegawa, Nina Orwitz, David S Quinn, David Pearson, Dexiu Bu, Pedro Milanez-Almeida and 10 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Science translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04318327 (Phase I, Open Label, Study of B-cell Maturation Antigen), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04318327 phase1terminatednot on this map

Phase I, Open Label, Study of B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Multiple Myeloma

TypeinterventionalSponsorNovartis PharmaceuticalsRan2020 to 2025Enrolled96ConditionsMultiple MyelomaArmsPHE885
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Adam S SperlingDana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-9369-4413
Benjamin A DermanSection of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL 60637, USA.ORCID 0000-0002-4070-1819
Sarah NikiforowDana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0009-0001-2711-5575
Alejandro AlonsoDana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0009-0000-6283-7859
Shuntaro IkegawaDana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-0337-9867
Nina OrwitzNovartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.ORCID 0000-0003-4087-1428
David S QuinnNovartis BioMedical Research, Cambridge, MA 02139, USA.ORCID 0000-0002-5335-8968
David PearsonNovartis BioMedical Research, Basel 4056, Switzerland.
Dexiu BuNovartis BioMedical Research, Cambridge, MA 02139, USA.
Pedro Milanez-AlmeidaNovartis BioMedical Research, Cambridge, MA 02139, USA.ORCID 0000-0001-8285-957X
Jennifer MatarazaNovartis BioMedical Research, Cambridge, MA 02139, USA.
Omar NadeemDana-Farber Cancer Institute, Boston, MA 02215, USA.
Jessica LiegelBeth Israel Deaconess Medical Center, Boston, MA 02215, USA.ORCID 0009-0007-8014-706X
Anita D'SouzaMedical College of Wisconsin, Milwaukee, WI 53226, USA.
Allison CharlesNovartis BioMedical Research, Cambridge, MA 02139, USA.
Marc CrediNovartis BioMedical Research, Cambridge, MA 02139, USA.
Jerome RitzDana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0001-5526-4669
Andrzej J JakubowiakSection of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL 60637, USA.ORCID 0000-0002-2597-6822
Serena De VitaNovartis BioMedical Research, Cambridge, MA 02139, USA.
Nikhil C MunshiDana-Farber Cancer Institute, Boston, MA 02215, USA.

Funding

Defining mechanisms of thalidomide analog resistanceK08CA252174 · NCI · DANA-FARBER CANCER INST · PI SPERLING, ADAM · 2020 to 2024
$1.3M
Early diagnosis of light chain amyloidosisR01HL166339 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Anita D'Souza · 2023 to 2026
$1.1M
NCI NIH HHS K08 CA252174NHLBI NIH HHS R01 HL166339
6 · The paper itself

Abstract

Traditional manufacturing of B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cell therapies is prolonged, leading to reduced patient access, T cell exhaustion, and consequently limiting therapeutic efficacy. To address this issue, we developed durcabtagene autoleucel, a BCMA-directed CAR T cell therapy manufactured using a rapid platform aimed at preserving T cell stemness. Here, we present the primary findings of part A of a phase 1 study (NCT04318327) of durcabtagene autoleucel in patients with relapsed/refractory multiple myeloma (r/r MM). The primary objective was safety; secondary objectives included response rates, cellular kinetics, immunogenicity, and manufacturing feasibility. Durcabtagene autoleucel was successfully manufactured for all 55 patients (median vein-to-vein time, 24 days) and given as a single infusion at one of four flat target doses (2.5 × 10

Indexed as

Immunotherapy, AdoptiveMultiple MyelomaAdultAgedB-Cell Maturation AntigenFemaleHumansMaleMiddle AgedReceptors, Chimeric AntigenRecurrenceT-LymphocytesTreatment OutcomeB-Cell Maturation AntigenReceptors, Chimeric Antigen

Identifiers

PMID42202046
PMCPMC13427373

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.